The bioluminescent response for CoCl₂ (a) and ZnSO₄ (b) of pILACoaR_WT and pILACoaR_NiCoZia. by Gábor Patyi (11846776)

Intradermal testing. by Ana Leda F. Longhini (226617)

Assessment of the relationship between adiposity, Sirtuin 1, and miR-30a-5p in a mixed-ancestry population in Bellville South, Cape Town. by Babalwa Gaxamba (20810513)

“…</p><p dir="ltr"><b>Study Results</b>: A total of 150 females and 150 males were selected for this study with an average age of 50 years. miR-30a-5p expression was significantly higher in overweight and obese participants compared to normal-weight individuals. …”

ASYN biochemical state. by Diana F. Lázaro (659832)

Basal medium with autologous plasma (AP) or autologous platelet lysate (APL) results in loss of cell surface marker phenotype and impaired growth respectively. by Ana Leda F. Longhini (226617)

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme by Alexandra Sufit (3270084)

“…GBM cell lines (A172, SF188, U251) were treated in vitro with increasing doses of UNC2025 (50-400nM). …”

<i>In Situ</i> TEM Technique Revealing the Deactivation Mechanism of Bimetallic Pd–Ag Nanoparticles in Hydrogen Sensors by Xueqing Wang (210284)

DataSheet_2_The predictive value of free thyroxine combined with tubular atrophy/interstitial fibrosis for poor prognosis in patients with IgA nephropathy.csv by Bixia Yang (18550324)

“…The renal composite outcomes were defined as: (1) ESRD, defined as eGFR < 15 ml/(min·1.73 m²) or initiation of renal replacement therapy (hemodialysis, peritoneal dialysis, renal transplantation); (2) serum creatinine doubled from baseline; (3) eGFR decreased by more than 50% from baseline. The predictive value was determined by the area under the curve (AUC). …”

DataSheet_1_The predictive value of free thyroxine combined with tubular atrophy/interstitial fibrosis for poor prognosis in patients with IgA nephropathy.docx by Bixia Yang (18550324)

“…The renal composite outcomes were defined as: (1) ESRD, defined as eGFR < 15 ml/(min·1.73 m²) or initiation of renal replacement therapy (hemodialysis, peritoneal dialysis, renal transplantation); (2) serum creatinine doubled from baseline; (3) eGFR decreased by more than 50% from baseline. The predictive value was determined by the area under the curve (AUC). …”

Sequence parameters. by Tobit Führes (12647099)

“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i>₁ = 0), acceleration-compensated (<i>M</i>₁ = <i>M</i>₂ = 0), 84%-<i>M</i>₁–<i>M</i>₂-compensated, 67%-<i>M</i>₁–<i>M</i>₂-compensated) at b-values of 50 and 800 s/mm² at a constant echo time of 70 ms. …”

ADC maps of one volunteer. by Tobit Führes (12647099)

“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i>₁ = 0), acceleration-compensated (<i>M</i>₁ = <i>M</i>₂ = 0), 84%-<i>M</i>₁–<i>M</i>₂-compensated, 67%-<i>M</i>₁–<i>M</i>₂-compensated) at b-values of 50 and 800 s/mm² at a constant echo time of 70 ms. …”

Absolute values of <i>M</i>₁ and <i>M</i>₂. by Tobit Führes (12647099)

“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i>₁ = 0), acceleration-compensated (<i>M</i>₁ = <i>M</i>₂ = 0), 84%-<i>M</i>₁–<i>M</i>₂-compensated, 67%-<i>M</i>₁–<i>M</i>₂-compensated) at b-values of 50 and 800 s/mm² at a constant echo time of 70 ms. …”

Liver azoxystrobin residues after 1 and 2 months treatment with different doses of azoxystrobin on male rats. by Ekramy Halawa (11785086)

Death probability (%) of newly developed branches of persimmons according to the densities of <i>P</i>. <i>shantungensis</i> egg masses. by Sunghoon Baek (7042535)

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”